Last reviewed · How we verify
AK112, nab-paclitaxel, gemcitabine
Inhibits microtubule dynamics by binding to tubulin, thereby inhibiting cell division
Inhibits microtubule dynamics by binding to tubulin, thereby inhibiting cell division Used for Breast cancer, Non-small cell lung cancer.
At a glance
| Generic name | AK112, nab-paclitaxel, gemcitabine |
|---|---|
| Sponsor | Akeso |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Nab-paclitaxel is a microtubule inhibitor that works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Approved indications
- Breast cancer
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer (PHASE1, PHASE2)
- A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer (PHASE2)
- Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK112, nab-paclitaxel, gemcitabine CI brief — competitive landscape report
- AK112, nab-paclitaxel, gemcitabine updates RSS · CI watch RSS
- Akeso portfolio CI